This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
BIO-Europe Spring

Why the Netherlands is a major player in the global life sciences and health industry

Posted by on 15 February 2018
Share this article

Why the Netherlands is a major player in the global life sciences and health industry - EBD GroupAfter a successful conference in 2012, BIO-Europe Spring® is back in Amsterdam. In the Netherlands, citizens, researchers, government, and entrepreneurs collaborate within the quadruple helix. Together they pioneer smart solutions all along the drug development chain that boost health, innovation, and affordability.

The impressive Dutch contributions to advance the world’s medical science go way back, featuring famous scientists such as Antoni van Leeuwenhoek, the first microbiologist. Today, we still are a major player in the global life sciences and health industry. We hold a strong technological position in molecular imaging, medical informatics, biopharmaceuticals, human and veterinary vaccines, regenerative medicine and biomaterials, medical technology and health infrastructure.

Our signature public-private partnerships bring together bright minds, connecting early research, product development, and commercialization. The foundation of the Dutch LSH sector is a solid and accessible scientific backbone, offering biotech companies the scientific excellence necessary to thrive in a competitive global market.

With a growing economy, outstanding scientific progress, a climate of ambitious entrepreneurship and a new fresh government in place, everything seems aligned to foster the further growth of the Dutch Life Sciences & Health sector.

– Hans Schikan, chairman a.i. of Top Sector Life Sciences & Health

The Dutch life sciences and health sector are on the rise: over the past decade, the sector has doubled in size. It belongs to the top European biotech hubs with 667 biotech companies within a 120-mile radius. The recent decision that the European Medicines Agency (EMA) will relocate to the Netherlands will further strengthen our position as a hot spot on the global life sciences and health map. Within a stone’s throw from Schiphol Airport, EMA brings over 2,250 fulltime jobs, EUR 150 million direct expenditure and many incoming visitors. We can’t wait to welcome the agency in 2019!

Where healthcare is concerned, only the best is good enough. Together we will, therefore, maintain committed to vital functioning citizens in a healthy economy. Come and meet the Dutch at BIO-Europe Spring, booth #72, and join us in our mission to revolutionize drug development. We are looking forward to welcoming you!

Looking for a sneak preview of what to expect at BIO-Europe Spring, March 12 – 14 in Amsterdam? Have a look at the Health~Holland BIO-Europe Spring Special!

Why the Netherlands is a major player in the global life sciences and health industry - EBD group

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down